CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?
CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States
CorMedix Inc. to Present at the Cantor Global Healthcare Conference
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
Buy Rating on Cormedix Affirmed Amidst DefenCath's Strong Market Entry and Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
JMP Securities analyst Jason Butler maintains $CorMedix(CRMD.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 37.4% and a